Celltrion Healthcare Gears Up For Infliximab SC Launch
UK Commercial Head Reveals Strategy For Innovative Biosimilar Infliximab
• By David Wallace
Generate a summary of this article
Listen to this article
As Celltrion Healthcare prepares to roll out Remsima SC, its subcutaneous infliximab, in Europe – starting in the UK and Germany – Celltrion Healthcare’s UK commercial head, Matthew Eddleston, speaks to Generics Bulletin about how the innovative biosimilar will be positioned in the market.
Highlighting Remsima (infliximab) SC’s innovative aspects will be at the heart of Celltrion Healthcare’s strategy • Source: Shutterstock
Having late last year received a pan-European marketing authorization for the world’s first subcutaneous formulation of infliximab, Celltrion Healthcare is preparing to launch the Remsima SC product imminently in its first European markets, the UK and Germany. (Also see "Celltrion’s Remsima SC Ready For Early 2020 Launch" - Generics Bulletin, 26 November, 2019.)
Ahead of Remsima SC’s launch, Celltrion Healthcare’s UK commercial head and vice-chair of the British Biosimilars Association, Matthew Eddleston, spoke...
Stay ahead of every shift in generics and biosimilars.
Generics Bulletin brings you the latest updates that matter for the off-patent industry.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
An abbreviated licensure pathway for biologics was created by the 2009 Biologics Price Competition and Innovation Act. Biologics demonstrated to be biosimilar to or interchangeable with FDA-approved products can use the 351(k) biologics license application pathway. Biosimilars BLAs submitted under the 351(k) pathway have a 12 month user fee goal for FDA action. Updated weekly.
Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.
We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.
